Gilead (NASDAQ: GILD) announced total revenues for 3Q07 of $1.06B, up 41% percent compared to total revenues of $748.7MM for 3Q06, along with record product sales of $962MM, up 44% over 3Q06! An amazing 90-day run, but what I am most interested in is how is Letaris® (ambrisentan) faring?
Now don’t quote me here because I am unable to recall/validate my sources (and I feel awful about that) but from what I have heard that with a field sales team focusing on large PAH centers Letairis® did about $6MM in its first quarter of sales and a forecast of ~$15MM for '07. The parity pricing with rival Actelion Pharma's Tracleer® (~40K/yr) has aided with reimbursement by Medicaid in 49 states, a strong label, and 9 of the top 20 managed care plans have given approval; combine these elements and Letairis should have a potent 2008 and aid a lot of people in the process. After perusing some of the PAH message boards this appears to be the tone…
"It is amazing how much better I feel. Some days I feel almost normal. Less side effects for me than the Tracleer."
If you enjoyed this post get free email updates (here).